Skip to Main Content

++

INTRODUCTION

++

dornase alfa (dor-nase al-fa)

Pulmozyme

Classification

Therapeutic: cystic fibrosis therapy adjuncts

Pharmacologic: pulmonary enzymes

++
Indications
++

Adjunct management (with standard therapy) of cystic fibrosis.

++
Action
++

Breaks down excessive amounts of DNA found in the respiratory tract of patients with cystic fibrosis. Excessive DNA contributes to increased sputum viscosity and risk of infection. Therapeutic Effects: Decreased infection rates and requirement for parenteral anti-infectives. Improved pulmonary function.

++
Adverse Reactions/Side Effects
++

EENT: sore throat, voice alteration, conjunctivitis, hoarseness, rhinitis. Resp: cough, dyspnea. CV: chest pain. Derm: rash. Misc: fever.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Assess the quantity and consistency of sputum to help document whether this drug is successful in reducing the viscosity of respiratory secretions.

  • Monitor any chest pain and attempt to determine if pain is drug-induced or caused by cardiovascular dysfunction (e.g., angina that occurs during exercise).

  • Assess any breathing problems, and report severe or persistent cough or difficult, labored breathing.

++
Interventions
++

  • When implementing airway clearance techniques or other pulmonary interventions, attempt to intervene when the drug has produced mucolytic effects. Effects typically begin 15 min after inhalation.

  • Design and implement breathing exercises to maximize ventilation and help prevent infections caused by pulmonary congestion.

++
Patient/Client-Related Instruction
++

  • Counsel patient and family/caregivers on proper inhalation techniques. Emphasize the need to adhere to the recommended dose and frequency of inhalations.

  • Instruct patient and family/caregivers to report other troublesome side effects such as severe or prolonged headache, skin rash, fever, nasal inflammation, eye irritation, sore throat, hoarseness, or voice changes.

++
Pharmacokinetics
++

Absorption: Negligible absorption following inhalation.

++

Distribution: Action is primarily local.

++

Metabolism and Excretion: Unknown.

++

Half-life: Unknown.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (effect on noted parameters)

ROUTE ONSET PEAK DURATION
Inhalation within 15 min* 3 days-1 wk weeks-months 48 hr

*Significant concentrations in sputum.

Improvement in respiratory function.

Decreased incidence of respiratory tract infections.

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity to dornase alfa or Chinese Hamster Ovary cell products.

++

Use Cautiously in: Children (incidence of cough, rhinitis, and rash is increased); Pregnancy or lactation (safety not established).

++
Interactions
++

Drug-Drug: None significant.

++
Route/Dosage
++

Inhaln (Adults and Children): 2.5 mg 1–2 times daily.

++
Availability
++

Solution for inhalation: 1 mg/mL in 2.5-mL single-use ampules.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.